reported the in vivo antitumor effects of hellebrigenin [29], and they also indicated that at a dose of 2.5 mg/kg, hellebrigenin reduced tumour weight and induced alterations in the expression of apoptotic proteins, including the upregulation of cleaved caspase‐3, caspase‐9 and Bax and the downregulation of Bcl‐2. Here, BCL2 is linked to neoplasm.